Form 4: Health Catalyst COO Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 22,773 shares of common stock at a price of $7.6952 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Daniel LeSueur, the Chief Operating Officer of Health Catalyst, Inc., sold 22,773 shares of the company's common stock on December 4, 2024.
- The sale was executed at a price of $7.6952 per share.
- This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted by Mr. LeSueur on March 7, 2024.
- Following the transaction, Mr. LeSueur directly owns 96,462 shares of Health Catalyst common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the technology and healthcare sectors, such as Cerner (now Oracle Health) and Veeva Systems.
- These plans allow insiders to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The volume of shares sold by Mr. LeSueur is not unusual for an executive at his level, and the price is consistent with the market price of HCAT stock at the time of the transaction.
Stakeholder Impact
- The stock sale by a key executive may cause some minor short-term fluctuations in the stock price, but is unlikely to have a significant long-term impact on shareholders.
- The sale does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2024-03-07 | Date the 10b5-1 trading plan was adopted by Daniel LeSueur. |
| 2024-12-04 | Date of the stock sale transaction. |
| 2024-12-06 | Date the Form 4 was signed. |
Keywords
Health Catalyst, HCAT, insider trading, Form 4, 10b5-1 plan, stock sale, Daniel LeSueur, Chief Operating Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.